** Gene therapy company MeiraGTx Holdings' shares MGTX.O rise 30.3% to $8.36 - highest since June 2023
** MGTX says it will collaborate with Hologen to form a joint venture called Hologen Neuro AI to develop experimental gene therapy AAV-GAD to treat Parkinson's disease
** Parkinson's disease is a brain condition that causes problems with movement, mental health, sleep, pain and other health issues
** MGTX will receive $200 million in upfront payment for the venture and $230 million to develop the gene therapy AAV-GAD, which is currently in late-stage development
** MGTX says it will retain 30% ownership in the joint venture and will lead all clinical development and manufacturing
** Separately, MGTX posts 2024 revenue of $33.28 mln, compared to $14.02 mln a year earlier
** Up to last close, MGTX had risen 5.6% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.